CellaVision AB (CEVI) AI Stock Analysis

• Market Cap: $4.07B
• Dividend Yield: 1.47%
• Average Volume (3M): 11.82K
• Price to Earnings (P/E): 26.9
• Beta (1Y): 0.98
• Revenue Growth: 3.45%
• EPS Growth: 4.22%
• Country: SE
• Employees: 228
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): 1.60
• Shares Outstanding: 23,851,547
• 10 Day Avg. Volume: 12,293
• 30 Day Avg. Volume: 11,822
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.03
• Enterprise Value/Revenue: 5.63
• Enterprise Value/Gross Profit: 8.22
• Enterprise Value/Ebitda: 17.81
• 1Y Price Target: $206.99
• Price Target Upside: 21.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 65 Neutral
• Price Target: kr187.00 ▲(9.61%Upside)

CellaVision AB's strong financial health and profitability are significant strengths, positioning it well in the Medical Devices industry. However, bearish technical indicators and a moderate valuation suggest caution in the short term.

CellaVision AB Business Overview & Revenue Model

Company Description

CellaVision AB is a Swedish-based medical technology company that specializes in digital solutions for medical microscopy in the field of hematology. The company develops and sells innovative software and hardware solutions that automate and enhance the process of analyzing blood and other body fluids. By improving the efficiency and accuracy of hematology diagnostics, CellaVision aims to support laboratories and healthcare institutions in delivering better patient care.

How the Company Makes Money

CellaVision AB generates revenue primarily through the sale of its digital microscopy systems, which include both hardware components and proprietary software. The company's key revenue streams involve direct sales to healthcare institutions, laboratories, and distributors, as well as recurring revenue from software licenses and service agreements. CellaVision's strategic partnerships with leading diagnostic equipment manufacturers and distributors enhance its market reach and contribute significantly to its earnings. Additionally, the company invests in research and development to continually innovate its product offerings, ensuring sustained demand and profitability in the competitive healthcare technology market.

CellaVision AB Financial Statement Overview

Summary

CellaVision AB exhibits strong financial health with robust revenue growth and profitability. The balance sheet is stable with low leverage, providing resilience against economic fluctuations. Cash flow generation is healthy, although there is potential to enhance free cash flow conversion. Overall, CellaVision is well-positioned in the Medical Devices industry.

Income Statement

CellaVision AB has demonstrated strong growth with a consistent increase in total revenue over the years, achieving a revenue growth rate of 3.41% in the TTM. The gross profit margin is robust at 68.47% for the TTM, indicating effective cost management. The net profit margin of 20.34% reflects solid profitability. Both EBIT and EBITDA margins are strong, at 26.20% and 31.53% respectively, showcasing operational efficiency.

Balance Sheet

The balance sheet of CellaVision is solid with a low debt-to-equity ratio of 0.03, indicating minimal leverage. The equity ratio stands at a healthy 80.31%, showcasing financial stability. Return on equity is impressive at 18.14%, reflecting efficient use of shareholder funds. However, the low liability level might suggest underutilized leverage potential.

Cash Flow

CellaVision's cash flow position is stable with a positive free cash flow growth rate. The operating cash flow to net income ratio is 1.24, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio at 0.44 suggests room for improvement in converting earnings into free cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	723.22M	677.29M	639.34M	565.55M	471.44M
Gross Profit	487.07M	463.04M	438.32M	392.30M	313.04M
EBITDA	219.75M	207.25M	190.87M	193.60M	124.60M
Net Income	140.72M	130.31M	118.33M	125.34M	89.48M
Balance Sheet
Total Assets	1.01B	928.71M	891.75M	825.21M	668.02M
Cash, Cash Equivalents and Short-Term Investments	149.43M	121.64M	108.05M	130.29M	102.26M
Total Debt	26.85M	64.70M	102.50M	136.65M	132.78M
Total Liabilities	196.16M	212.32M	250.12M	281.93M	238.41M
Stockholders Equity	815.73M	716.39M	641.63M	543.28M	429.62M
Cash Flow
Free Cash Flow	120.69M	109.96M	67.85M	75.41M	37.47M
Operating Cash Flow	198.44M	196.44M	137.28M	159.72M	71.12M
Investing Cash Flow	-76.01M	-85.53M	-70.01M	-84.34M	-34.96M
Financing Cash Flow	-95.09M	-97.04M	-90.41M	-48.48M	-35.22M

CellaVision AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 170.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CEVI, the sentiment is Negative. The current price of 170.6 is below the 20-day moving average (MA) of 179.34, below the 50-day MA of 184.94, and below the 200-day MA of 197.49, indicating a bearish trend. The MACD of -2.61 indicates Positive momentum. The RSI at 36.45 is Neutral, neither overbought nor oversold. The STOCH value of 27.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CEVI.

CellaVision AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAD.B	72 Outperform	€1.16B	45.15	7.87%	―	-10.34%	-59.69%
CEVI	65 Neutral	$4.07B	26.92	18.65%	1.47%	3.45%	4.22%
SUS	64 Neutral	kr7.39B	52.37		―	12.41%	-32.19%
SECARE	60 Neutral	kr6.01B	92.11	0.87%	0.66%	5.41%	-14.85%
Sector *	52 Neutral	kr6.05B	8.94	-59.74%	2.10%	25.95%	22.55%
XSPRAY	47 Neutral	kr1.83B	―	-42.24%	―	―	-19.44%
VICO	45 Neutral	kr2.08B	―	-40.15%	―	―	63.85%

CellaVision AB Corporate Events

CellaVision Reports Robust Q2 2025 Performance Amid Regional Variations

CellaVision’s Q2 2025 report shows a robust performance with a 7.6% organic sales growth despite mixed regional results. The APAC region saw significant growth due to increased shipments to China, while the Americas and EMEA experienced moderate growth. The company is advancing strategic priorities, including clinical trials for bone marrow analysis and software upgrades, and maintains a strong financial position. The departure of CFO Magnus Blixt marks a significant leadership change.

CellaVision to Release Q2 2025 Financial Report and Host Webcast

CellaVision AB announced it will release its second-quarter 2025 financial report on July 18, 2025, and will host a conference call and webcast for analysts, investors, and media. This event, led by CEO Simon Østergaard, will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders’ perspectives on CellaVision’s market position and growth trajectory.

CellaVision Announces CFO Departure Amidst Continued Growth

CellaVision AB announced the departure of its CFO, Magnus Blixt, who will leave the company on July 18, 2025, after twelve years of service. His contributions have been significant in the company’s growth and success, and the search for his replacement will begin immediately. This change in management comes as CellaVision continues to expand its product portfolio and market presence, maintaining its focus on delivering profitable growth.

CellaVision AB AGM Approves Financials and Strategic Resolutions

At its Annual General Meeting, CellaVision AB resolved to adopt the financial statements for 2024, approve a dividend of SEK 2.50 per share, and re-elect key board members, including Mikael Worning as Chairman. The AGM also authorized the board to repurchase and transfer shares, aiming to optimize capital structure and enhance shareholder value, while facilitating working capital procurement and ownership base expansion.